Condition: Obese With Comorbidities · Obese Patients (BMI ≥ 30 kg/m²) · Sponsor: Aphaia Pharma US LLC
The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD 012 and APHD 002) combined with a gel composition, compared with two different doses of the placebo beads formulations (APHP 012 and APHD 002) combined with a gel composition in obese subjects with weight related comorbidities.
This description comes directly from the study's public registry record.
Steffen S Bolz, Prof. (Univ. Toronto) Dr. med. · +41/41/78496331 · bolz@aphaiapharma.com
Susanne K Grafe, MD · +41/41/78496331 · grafe@aphaiapharma.com
Always discuss trial participation with your own doctor first.
| LTD "Israeli-Georgian Medical Research Clinic Healthycore" | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
| LTD "New Hospitals" | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
| LTD "Acad. G. Chapidze Emergency Cardiology Center" | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
| LTD "Diacor" | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
| NNLE "Jo Ann University Hospital" | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
| LTD The First Medical Center | Tbilisi, K'alak'i T'bilisi, Georgia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07008456